Brief: Propanc Biopharma Provides Corporate Update And Reports First Quarter 2025/26 Results
17/11/2025 13:52
Propanc Biopharma Inc PPCB.O: PROPANC BIOPHARMA PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2025/26 RESULTS PROPANC BIOPHARMA INC QTRLY EPS $-0.39 Source text: ID:nGNXb7qKjB Further company coverage: PPCB.O
Recent news on Propanc Biopharma
See all newsNASDAQ TRADE HALT HALT NEWS PENDING AT 09:29 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition With Prp In Pancreatic Cancer Models, Contrasting Profile With Revolution Medicines’ Daraxonrasib
Brief: Propanc Biopharma Registers Resale Of 6,500,000 Shares Of Common Stock - SEC Filing
Brief: Propanc Biopharma To File Cta In Australia For Phase 1B Study In 30–40 Advanced Cancer Patients